Huland H, Otto U, Droese M
Eur Urol. 1983;9(6):346-9. doi: 10.1159/000474121.
We followed 67 patients with superficial bladder cancer (TA, T1) for 12-48 months (mean, 26.8 months) after surgical removal of the tumors. Every 3-4 months, when the patients came for cystoscopic control, we evaluated serum and urinary carcinoembryonic antigen (CEA), urinary cytology, serum rheumatoid factors, and urinary IgG, IgA, and IgM concentrations. The purpose was to look for markers or prognostic factors in patients with superficial bladder carcinoma other than characteristics of the excised tumors themselves. We emphasized data that can be obtained on patient follow-up. Our results were correlated with tumor recurrence and tumor progression rates. In contrast with other reports, only urinary immunoglobulins (especially IgG) proved to have prognostic value. However, urinary CEA and (even more so) urinary cytology are fairly good tumor markers: they were positive when the bladder tumors were present and, in the case of recurrence, before recurrent tumors were visible.
我们对67例浅表性膀胱癌（TA、T1期）患者在肿瘤手术切除后进行了12至48个月（平均26.8个月）的随访。每3至4个月，当患者前来进行膀胱镜检查时，我们评估血清和尿癌胚抗原（CEA）、尿细胞学、血清类风湿因子以及尿IgG、IgA和IgM浓度。目的是寻找除切除肿瘤本身特征之外的浅表性膀胱癌患者的标志物或预后因素。我们强调了在患者随访过程中可获得的数据。我们的结果与肿瘤复发率和肿瘤进展率相关。与其他报告不同，只有尿免疫球蛋白（尤其是IgG）被证明具有预后价值。然而，尿CEA以及（更重要的是）尿细胞学是相当好的肿瘤标志物：当膀胱肿瘤存在时它们呈阳性，并且在复发情况下，在复发性肿瘤可见之前就呈阳性。
